Finding a pharmaceutical company that boasts a strong product lineup, a robust development pipeline, and a stable, generous dividend is a rare discovery. AbbVie (NYSE: ABBV), a “Dividend King” having raised its payout for over 50 consecutive years, stands out as a compelling long-term value proposition in volatile markets. Its appeal lies in a portfolio of 12 blockbuster drugs each generating over $1 billion in annual sales, a dividend yield around 3%, and a savvy patent extension strategy.
Unlike peers reliant on a single blockbuster, AbbVie has built a scaled and diversified product matrix. Full-year 2024 data revealed at least 12 such blockbusters, including star performers like Skyrizi (for dermatological conditions) and Botox (aesthetic medicine). Together, this portfolio contributed nearly $47 billion in net revenue across multiple therapeutic areas.
The company’s most recent quarterly report showed net revenue rising nearly 7% year-over-year to $15.4 billion. Adjusted earnings per share grew more significantly, increasing 12% to $2.97. Despite the constant patent cliff pressures faced by major pharma companies, AbbVie has demonstrated remarkable profit stability, maintaining free cash flow between $16.8 billion and $24.2 billion over the past five years.
Supported by its substantial cash flow, AbbVie consistently rewards shareholders. The current quarterly dividend is $1.64 per share, yielding approximately 3%—well above the S&P 500 average of around 1.2%. Notably, the dividend has soared by 221.6% over the past decade, and with over 50 years of consecutive annual increases, it holds the elite status of a “Dividend King.”
A core competitive advantage for AbbVie is its mastery of patent strategy. The prime example is Humira, its former flagship drug. After its 2003 launch, the company employed a “patent thicket” to fend off biosimilar competition in the U.S. until 2023, effectively extending its market exclusivity for nearly two decades. This capability is reflected in the stock’s performance, delivering a total return of 494% over the past ten years.
New flagship drugs Skyrizi and Rinvoq are now driving growth. In the first half of 2025, Skyrizi sales surged 69% year-over-year to $7.8 billion. Rinvoq, an arthritis treatment, generated $3.7 billion in sales during the same period. Even with Humira sales more than halving, total revenue for the first half of 2025 still grew by 8%. The complex manufacturing and administration processes for these injectable drugs also provide additional opportunities to extend their exclusivity periods.
With shares recently at $222.59, AbbVie’s market capitalization reaches $393 billion, and its dividend yield stands at 3.1%. If the company can successfully replicate its Humira patent protection strategy for Skyrizi and Rinvoq, shareholders can likely expect continued dividend growth in the coming decade. For investors seeking a dual engine of growth and income, this pharmaceutical giant, balancing innovation with shareholder returns, deserves close attention.
